WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259)), has entered into a memorandum of understanding (MOU) with South Korea-based biotech company AbTis. This collaboration aims to enhance innovation in antibody-drug conjugate (ADC) therapeutics and create new opportunities for global clients by integrating AbTis’ proprietary site-selective conjugation platform, AbClick, with WuXi XDC’s comprehensive discovery services and all-in-one development and manufacturing platform.
Collaboration Details
Under the terms of the MOU, WuXi XDC will incorporate AbTis’ advanced site-selective conjugation technologies, including the AbClick Platform. This platform utilizes affinity peptide-assisted linkers to enable precise and efficient antibody-drug conjugation. The integration of these technologies will enhance the precision and efficiency of ADC development.
Market Expansion and Synergies
The collaboration will facilitate potential partnerships between AbTis and WuXi XDC’s extensive client network. This will expand the global reach of AbTis’ technologies and unlock synergistic market opportunities. By combining AbTis’ innovative conjugation platforms with WuXi XDC’s integrated services, the partnership positions both companies to play a pivotal role in the growing ADC market.-Fineline Info & Tech
Leave a Reply